C12Y 207/11026
Tau-protein kinase
Official title: Tau-protein kinase (2.7.11.26)
C12Y207/11026 (Tau-protein kinase) appears on 13 US grants and 26 published applications in this corpus.
Search patents in C12Y- Granted patents
- 13
- Published applications
- 26
- Assignees
- 23
- Inventors
- 54
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 1 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 2 |
| 2012 | 0 | 1 |
| 2013 | 1 | 2 |
| 2014 | 0 | 2 |
| 2015 | 1 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 1 | 2 |
| 2019 | 0 | 1 |
| 2020 | 2 | 1 |
| 2021 | 0 | 2 |
| 2022 | 0 | 0 |
| 2023 | 1 | 0 |
| 2024 | 0 | 1 |
| 2025 | 1 | 3 |
| 2026 | 1 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Small extracellular vesicles expressing a dominant negative AMPK alpha 1 mutant for use in the treatment of obesity26 May 2026US 12,637,660 B2Centre National de la Recherche Scientifique (CNRS)
- Recombinant replication competent viruses comprising a coding region for glycogen synthase kinase-3 (GSK3) and methods of killing aberrant cells25 Feb 2025US 12,233,096 B2ORCA Therapeutics B.V.
- Regulation of fungal fruiting body development6 Jun 2023US 11,668,702 B2The Chinese University of Hong Kong
- Lateral flow device and method of use17 Mar 2020US 10,591,477 B2Bio-Rad Laboratories, Inc.
- Methods for molecular classification of fatty liver by high-throughput protein post-translational modifications17 Mar 2020US 10,591,478 B2Roseman University of Health Sciences
- Methods of targeting glycogen synthase kinase 3 beta in nk cells6 Aug 2026US 2026/0226413 A1Research Institute At Nationwide Children's Hospital
- Use of glycogen synthase kinase-3 (gsk3) as protease, and gsk3-based proteolysis-targeting chimera (protac) and preparation method and use thereof19 Feb 2026US 2026/0049292 A1
- Compositions and methods for treating and preventing metabolic disorders11 Sep 2025US 2025/0281572 A1The Johns Hopkins University
- Small extracellular vesicles expressing a dominant negative ampk alpha 1 mutant for use in the treatment of obesity24 Apr 2025US 2025/0127864 A1Centre National de la Recherche Scientifique (CNRS)
- Treatment of severe and uncomplicated malaria23 Jan 2025US 2025/0025461 A1Nurex S.R.L.
Most cited
By later US patents
- Preventive or therapeutic agents for alzheimers disease a screening method of alzheimers disease and tau-protein kinase I originated from human being24US 5,837,853 AMitsubishi Chemical Corporation · 1998
- Screening method for therapeutic agents against Alzheimer's disease5US 6,071,694 AMitsubishi Chemical Corporation · 2000
- Gene encoding human tau-protein kinase I and use thereof4US 6,248,559 B1Mitsubishi Chemical Corporation · 2001
- Antisense modulation of glycogen synthase kinase 3 beta expression4US 6,323,029 B1Isis Pharmaceuticals, Inc. · 2001
- Nucleic acid encoding a Brain Derived Tau Kinase polypeptide and methods of use thereof2US 7,521,230 B2Board of Regents of the University of Nebraska · 2009